Value
4.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 4.0 |
ROIV · Why this verdict
Why Roivant Sciences (ROIV) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.3/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Brepocitinib is the single highest-priority clinical asset, meaning clinical trial failure, regulatory rejection, or a competitive setback in its target indication would remove the primary near-term value driver for the entire company at the current stage of development. Bear case | At least one additional late-stage pipeline program enters Phase 2 or Phase 3 development within 12 months, reducing the proportion of enterprise value attributable to brepocitinib alone. | →Stable |
| CounterFocused biotech holding companies like Roivant often create more value by concentrating resources on the highest-probability asset rather than diversifying prematurely into lower-conviction programs. | ||
Free cash flow is -13,202% of revenue, the Piotroski F-Score is only 2 out of 9, and there is no competitive moat, reflecting a pre-revenue company whose financials are entirely driven by clinical spending with no offsetting business quality metrics. Quality breakdown | Cash burn per quarter remains below $200 million as the company prioritizes high-return clinical investments while managing operating expenses, providing at least 18 months of runway. | →Stable |
| CounterA Piotroski F-Score and quality metrics are structurally inapplicable to a clinical-stage holding company; the relevant financial metric is cash runway versus the clinical milestone calendar, not earnings quality ratios. | ||
Roivant beat earnings estimates in 3 of the last 4 quarters with an average positive surprise of 8.2%, reflecting improving cost control and the company's ability to reduce cash losses faster than analysts expect quarter to quarter. Earnings | The beat streak extends to 5 consecutive quarters as clinical spend discipline allows quarterly losses to come in at least 5% better than consensus estimates. | →Stable |
| CounterBeating negative earnings-per-share estimates by small percentages does not change the fundamental trajectory; the company still needs a major clinical catalyst to justify its current market capitalization. | ||
Analyst consensus sees 30% upside to the price target of $33.97 from the current $30.03, with an analyst rating score of 8.4 out of 10 reflecting high conviction from covering analysts that clinical milestones can drive significant price appreciation. Sentiment breakdown | Price reaches at least $34 within 12 months as a clinical readout from the brepocitinib program converts analyst targets into realized gains. | →Stable |
| CounterAnalyst price targets in clinical-stage biotechs are based almost entirely on probability-weighted clinical success assumptions; a single trial setback can eliminate 50% to 100% of the analyst-implied upside overnight. | ||
Brepocitinib is the single highest-priority clinical asset, meaning clinical trial failure, regulatory rejection, or a competitive setback in its target indication would remove the primary near-term value driver for the entire company at the current stage of development.
→StableBear case
- Expectation
- At least one additional late-stage pipeline program enters Phase 2 or Phase 3 development within 12 months, reducing the proportion of enterprise value attributable to brepocitinib alone.
CounterFocused biotech holding companies like Roivant often create more value by concentrating resources on the highest-probability asset rather than diversifying prematurely into lower-conviction programs.
Free cash flow is -13,202% of revenue, the Piotroski F-Score is only 2 out of 9, and there is no competitive moat, reflecting a pre-revenue company whose financials are entirely driven by clinical spending with no offsetting business quality metrics.
→StableQuality breakdown
- Expectation
- Cash burn per quarter remains below $200 million as the company prioritizes high-return clinical investments while managing operating expenses, providing at least 18 months of runway.
CounterA Piotroski F-Score and quality metrics are structurally inapplicable to a clinical-stage holding company; the relevant financial metric is cash runway versus the clinical milestone calendar, not earnings quality ratios.
Roivant beat earnings estimates in 3 of the last 4 quarters with an average positive surprise of 8.2%, reflecting improving cost control and the company's ability to reduce cash losses faster than analysts expect quarter to quarter.
→StableEarnings
- Expectation
- The beat streak extends to 5 consecutive quarters as clinical spend discipline allows quarterly losses to come in at least 5% better than consensus estimates.
CounterBeating negative earnings-per-share estimates by small percentages does not change the fundamental trajectory; the company still needs a major clinical catalyst to justify its current market capitalization.
Analyst consensus sees 30% upside to the price target of $33.97 from the current $30.03, with an analyst rating score of 8.4 out of 10 reflecting high conviction from covering analysts that clinical milestones can drive significant price appreciation.
→StableSentiment breakdown
- Expectation
- Price reaches at least $34 within 12 months as a clinical readout from the brepocitinib program converts analyst targets into realized gains.
CounterAnalyst price targets in clinical-stage biotechs are based almost entirely on probability-weighted clinical success assumptions; a single trial setback can eliminate 50% to 100% of the analyst-implied upside overnight.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Roivant Sciences is a clinical-stage biopharma holding company with its entire near-term value concentrated in brepocitinib and a HanAll Biopharma partnership, currently burning cash at 13,202% of revenue while showing improving earnings beat trends and analyst consensus implying 30% upside from current levels.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 2.5 |
| Piotroski F | 2.2 |
- ▸Cash-burning: FCF -13202% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.4 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 2.9 |
- ▸Overbought (RSI 91)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 6.5 |
| erm sentiment | 5.0 |
Insider
3.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Notable insider selling — $27,437,151 (0.109% of mkt cap)
Peer rank
4.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 7.7 |
| growth rank | 1.3 |
Technical
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.6 |
| support resistance | 0.7 |
| 52w position | 9.7 |
Risk (lower is worse)
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.0 |
| days to cover | 5.4 |
| volatility | 4.1 |
| put call | 0.0 |
| implied vol | 3.6 |
| beta | 6.6 |
| debt equity | 3.0 |
- ▸Elevated put/call: 10.91
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 6.6 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:7.1>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:36d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.3=NEGATIVE
Warning (0)
none
Reward-to-Risk
-0.27
Upside
-4.0%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Momentum at 7.1 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-0.3=NEGATIVE.
The strongest dimensions are Momentum at 7.1, Catalyst at 5.8, and Sentiment at 5.5; the weakest are Quality at 1.2, Insider at 3.3, and Technical at 4.0. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -0.27 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Pipeline Concentration Brepocitinib
Trip ifPrice drops below $20, more than 33% below the current $30.03, on a clinical failure or regulatory hold for brepocitinib.
- P2Cash Burn Quality Floor
Trip ifCash and equivalents fall to less than 12 months of runway based on quarterly cash burn exceeding $150 million per quarter without a new financing or partnership milestone.
- P3Improving Earnings Beat Streak
Trip ifEPS surprise falls below 0% in at least 2 of the next 4 quarters, reversing the improving cost-control trend.
- P4Analyst Upside 30 Pct Consensus
Trip ifAnalyst consensus price target is revised below $25, more than 25% below the current $30 consensus target, indicating analysts have lost confidence in the clinical pipeline.